Market Outlook

By 2035, the U.S. Image-Guided Oncology Devices Market is projected to reach approximately USD 19.39 billion, expanding at a CAGR of 10.32% during the forecast period 2026–2035. The market is estimated at USD 7.26 billion in 2025, following an expansion from approximately USD 4.82 billion in 2021, USD 5.31 billion in 2022, USD 5.89 billion in 2023, and USD 6.55 billion in 2024. Values in this report are expressed in USD billions.

For the purpose of this report, image-guided oncology devices include equipment, procedural systems, navigation platforms and related therapeutic devices that use CT, cone-beam CT, MRI, ultrasound, fluoroscopy, angiography, PET-derived information, surface imaging or other visualization technologies to localize tumors, plan treatment, guide therapeutic delivery, verify positioning or monitor the treatment zone. The market includes image-guided radiation therapy systems, image-guided tumor ablation platforms, oncology navigation and robotic guidance systems, image-guided embolization and targeted delivery devices, and oncology-specific biopsy, localization and procedural planning systems. General diagnostic imaging systems used outside an oncology-guidance workflow, radiopharmaceuticals, oncology drugs and provider procedure fees are excluded to avoid overstating the addressable device market.

Demand is supported by the scale and increasing complexity of cancer care in the United States. Approximately 2.04 million new cancer cases were expected in the U.S. in 2025, while more than 18.6 million Americans were living with a history of cancer at the beginning of 2025. The survivor population is expected to surpass 22 million by 2035, increasing the need for repeated imaging, surveillance, recurrence management, focal treatment and treatment of metastatic disease. Radiation therapy remains relevant to more than half of patients with cancer during the course of their disease, making accurate target localization and treatment verification essential components of modern oncology infrastructure.

The market is moving beyond conventional image-guided radiation delivery toward an integrated precision-treatment ecosystem. Adaptive radiotherapy, cone-beam CT-guided linear accelerators, MRI-guided intervention, robotic needle placement, non-thermal histotripsy, MRI-guided laser ablation, cryoablation, microwave ablation, stereotactic body radiation therapy, surface-guided radiation therapy and artificial intelligence-assisted treatment planning are reshaping capital investment priorities.

Hospital procurement economics are also changing. U.S. cancer programs increasingly evaluate technology based on total treatment capacity rather than equipment specifications alone. Administrators are examining whether a platform can shorten planning time, reduce repeat imaging, increase daily treatment slots, support hypofractionated protocols, enable outpatient intervention, lower anesthesia requirements, reduce hospitalization and extend treatment to patients who are poor surgical candidates. These workflow benefits will increasingly determine which image-guided oncology platforms earn premium capital approval.

The market is expected to reach approximately USD 8.01 billion in 2026, crossing USD 11.86 billion by 2030 before approaching USD 19.39 billion in 2035. Growth will be disproportionately concentrated in adaptive radiotherapy, advanced tumor ablation, robotic image guidance, MRI-guided treatment and software-assisted procedural planning rather than conventional positioning equipment alone.

 

Introduction

According to the U.S. Image-Guided Oncology Devices Market Report, the market is positioned at the intersection of diagnostic imaging, interventional radiology, radiation oncology, surgical oncology and precision medicine. The fundamental clinical requirement is straightforward: cancer treatment becomes more valuable when clinicians can identify the target precisely, understand its relationship with surrounding anatomy, deliver therapy accurately and confirm that the intended tissue has been treated.

That principle has become increasingly important as oncology treatment shifts toward smaller targets, earlier-stage disease, oligometastatic disease, organ-preserving treatment and minimally invasive alternatives to open surgery. Image guidance is therefore moving from an optional technical enhancement to an integral component of many high-value cancer procedures.

The U.S. market has particularly favorable conditions for adoption because it combines a large cancer population with an extensive network of comprehensive cancer centers, academic medical centers, radiation oncology facilities, interventional radiology departments and high-volume hospital systems. The country also has a strong installed base of advanced CT, MRI, PET, fluoroscopy and radiation therapy equipment that can support expansion into increasingly sophisticated oncology workflows.

The economic structure of the market is distinct from conventional imaging. General CT or MRI procurement is often evaluated according to diagnostic throughput across multiple specialties. Image-guided oncology purchasing is more closely linked to procedure capture, treatment capacity, radiation oncology service-line revenue, interventional oncology expansion, specialist recruitment and the ability to retain complex cancer cases within a health system.

This difference is particularly important for manufacturers. Winning the U.S. market requires more than superior image quality. Providers increasingly expect interoperability between imaging, treatment planning, navigation, therapy delivery, oncology information systems and post-treatment documentation. Integration can directly affect patient setup time, physician labor, room utilization and the number of procedures that can be completed within existing capital infrastructure.

The addressable opportunity is also being widened by changing cancer treatment pathways. Approximately 316,950 new female breast cancer cases, 313,780 prostate cancer cases and 226,650 lung and bronchus cancer cases were estimated in the United States during 2025. These large patient populations support substantial demand for stereotactic radiation, image-guided biopsy, localization, brachytherapy guidance, thermal ablation, cryoablation, MRI-guided therapy and treatment verification.

Image-guided oncology is therefore becoming less defined by a single equipment category and more by a treatment architecture. Companies that can connect visualization with planning, navigation, therapy and verification will increasingly influence purchasing decisions across U.S. oncology departments.

 

Key Market Drivers: What’s Fueling the U.S. Image-Guided Oncology Devices Market Boom?

The first structural driver is the sustained burden of cancer. More than two million new invasive cancers were expected to be diagnosed nationally in 2025. Aging remains especially important because incidence for many solid tumors rises substantially among older adults. An older patient population also increases demand for nonsurgical treatment alternatives, because many patients have comorbidities that make major surgery less attractive.

Image-guided procedures fit this clinical requirement particularly well. Percutaneous ablation, stereotactic radiotherapy, image-guided brachytherapy and embolization can allow clinicians to treat selected patients with lower procedural trauma than open surgery. For health systems, this can translate into shorter recovery periods, increased outpatient management and better utilization of high-cost oncology infrastructure.

Radiation oncology is the second major demand engine. More than half of cancer patients receive radiation therapy during their treatment journey. Modern radiation delivery increasingly depends on imaging immediately before or during treatment to account for anatomical variation, respiratory movement, bladder or bowel filling, tumor regression and changes in patient positioning.

This requirement is increasing adoption of cone-beam CT, surface tracking, treatment-room CT, MRI-guided radiation platforms and adaptive planning. As treatment courses become shorter and individual radiation doses become larger, positioning errors become less tolerable. Stereotactic body radiation therapy and stereotactic radiosurgery therefore increase the clinical value of high-quality image guidance.

A third driver is the expansion of interventional oncology. Percutaneous tumor treatment has become increasingly relevant for liver, lung, kidney, bone and selected metastatic tumors. Radiofrequency ablation, microwave ablation, cryoablation, irreversible electroporation, laser ablation, focused ultrasound and emerging mechanical histotripsy technologies all depend to varying degrees on precise imaging.

The economic proposition is particularly attractive when a procedure can be performed through a small percutaneous access point, reduce operating-room requirements and permit shorter hospitalization. This makes interventional oncology attractive not only to interventional radiologists but also to hospital executives seeking to expand minimally invasive cancer treatment capacity.

The fourth driver is the growth of stereotactic and focal treatment. Oncology is becoming more anatomically precise as clinicians identify smaller lesions earlier and treat limited metastatic disease more aggressively in selected patients. In these workflows, millimeter-level targeting increasingly matters. High-resolution imaging, respiratory motion management, fiducial tracking, surface guidance and robotic positioning therefore become integral to the treatment pathway.

A fifth driver is hospital capital replacement. Many large U.S. cancer centers operate mature fleets of linear accelerators, CT simulators, angiography systems and interventional radiology equipment. Replacement decisions increasingly involve a technological step-up rather than like-for-like purchasing. Providers may replace conventional linacs with systems offering improved on-board imaging, adaptive workflows or surface guidance, while interventional radiology departments are adding advanced CT navigation and robotic capabilities.

A sixth driver is the expansion of proton and particle therapy infrastructure. The United States had 46 operating proton centers at the end of 2024 and approximately 18,200 patients received proton therapy nationally that year. By 2026, the operating U.S. proton center base had reached roughly 50 facilities, with additional projects and expansions under development. Particle therapy remains a relatively small component of total U.S. radiation procedures, but it represents a high-value image-guidance opportunity because accurate localization and treatment planning are critical to exploiting its dose-distribution advantages.

The seventh driver is the continuing transition toward value-based oncology. Technologies that help avoid complications, repeat procedures, geographic miss, unnecessary hospitalization or treatment delays can provide economic value beyond their acquisition price. This changes the selling proposition from “better imaging” to measurable procedural economics.

 

Innovation in Focus: How Manufacturers Are Raising the Bar?

Adaptive radiotherapy represents one of the most consequential innovation cycles in the market. Traditional radiation planning is generally based on anatomy captured before a treatment course begins. Adaptive workflows use updated imaging to identify anatomical changes and modify the treatment plan accordingly. This enables closer alignment between the treatment delivered and the patient’s current anatomy.

The commercial implications are substantial. Adaptive treatment can increase computational, imaging and workflow requirements, creating demand for integrated planning software, advanced on-board imaging, automated contouring and decision-support tools. Manufacturers that simplify these workflows can help hospitals expand adaptive treatment beyond specialized academic centers.

MRI guidance is another important frontier. MRI provides strong soft-tissue visualization without ionizing imaging radiation, making it particularly useful for prostate, brain, liver and other soft-tissue applications. MRI-guided radiation therapy and MRI-guided thermal treatment allow clinicians to visualize anatomy during therapy and, in selected applications, assess thermal effects.

Cone-beam CT is also advancing. Improved reconstruction algorithms and larger fields of view are moving CBCT from basic positioning toward increasingly diagnostic-quality visualization. Better treatment-room imaging can reduce dependence on separate simulation and verification steps while enabling more rapid adaptive workflows.

Robotic procedural guidance is changing interventional oncology. CT-guided tumor ablation traditionally requires substantial operator skill in translating two-dimensional images into three-dimensional needle trajectories. Robotic systems can assist with trajectory planning and instrument positioning, particularly where tumors are difficult to access or multiple probes must be positioned accurately.

Non-thermal ablation is creating a second important innovation cycle. Histotripsy mechanically destroys targeted tissue using focused ultrasound rather than thermal energy. Irreversible electroporation uses electrical fields to disrupt cell membranes. These approaches may broaden the types of tumors and anatomical locations that can be considered for focal treatment.

Cryoablation is simultaneously expanding into new indications. Its ice-ball visualization under imaging gives clinicians direct information about the treatment zone. Regulatory expansion into selected low-risk breast cancer applications further demonstrates how image-guided focal oncology can extend beyond traditional liver, kidney and lung intervention.

Artificial intelligence is becoming an enabling layer across the entire market. AI applications include automatic organ segmentation, treatment contouring, image registration, artifact reduction, tumor detection, radiation plan optimization, ablation-zone evaluation and workflow prioritization. The greatest commercial impact will come when these capabilities reduce physician or dosimetrist labor rather than simply adding another visualization feature.

Surface-guided radiation therapy is also gaining importance, particularly in breast, brain and stereotactic applications. Optical surface monitoring can support setup and motion detection without repeated ionizing imaging. When integrated with internal image guidance, these systems create a multilayer verification architecture.

The next competitive frontier will therefore be workflow orchestration. Device companies that integrate imaging, planning, patient positioning, therapy delivery, quality assurance and longitudinal oncology data will have greater strategic relevance than manufacturers selling isolated hardware.

 

Segmentation Insights

The U.S. Image-Guided Oncology Devices Market is segmented on the basis of product category, imaging modality, application, end user and region.

 

By Product Category

Image-Guided Radiation Therapy Systems

Image-guided radiation therapy systems represent the largest product category, accounting for an estimated USD 3.35 billion in 2025, or approximately 46% of the addressable market. The segment includes image-enabled linear accelerators, CT-guided treatment systems, MRI-guided radiation platforms, stereotactic radiation systems, image-guided brachytherapy equipment, patient-position verification and associated oncology guidance hardware.

Growth is being driven increasingly by adaptive treatment rather than simple installed-base expansion. Cancer centers replacing aging linear accelerators are prioritizing better on-board imaging, faster cone-beam CT acquisition, motion management and software integration.

Image-Guided Tumor Ablation Systems

Image-guided tumor ablation represented approximately USD 1.12 billion in 2025 within the defined market. Technologies include microwave ablation, radiofrequency ablation, cryoablation, laser ablation, high-intensity focused ultrasound, irreversible electroporation and histotripsy.

The segment is expected to record one of the fastest growth rates through 2035 as focal therapies expand across liver, kidney, lung, breast, prostate and metastatic lesions. Recurring probes, antennas and procedure-specific accessories make the category commercially attractive because revenue growth is tied to procedure volume after capital installation.

Oncology Navigation and Robotic Guidance Systems

Navigation, tracking and robotic guidance systems accounted for approximately USD 0.96 billion in 2025. These platforms support needle placement, trajectory planning, stereotactic procedures, neurosurgical oncology, minimally invasive ablation and complex lesion access.

Growth is strongly dependent on demonstrating that automation reduces procedure variability and improves throughput. Hospitals will resist expensive robotics that merely adds workflow steps, while systems that increase physician productivity or expand the number of treatable lesions can justify premium capital investment.

Image-Guided Embolization and Targeted Therapy Delivery Devices

This category represented approximately USD 1.02 billion in 2025. It includes catheters, microcatheters, guidewires, delivery platforms and procedure-specific devices used under fluoroscopic or angiographic visualization for embolization and localized treatment.

Liver-directed oncology remains particularly important. The segment benefits from repeat procedures and recurring consumable demand, making it less dependent on long capital replacement cycles than radiation therapy equipment.

Image-Guided Biopsy, Localization and Procedure Planning Devices

Image-guided biopsy, lesion localization and oncology procedure-planning devices accounted for approximately USD 0.81 billion in 2025. Demand is supported by precision tissue sampling, molecular oncology testing, stereotactic localization and pre-treatment planning.

As oncology becomes increasingly biomarker-driven, obtaining representative tissue safely becomes more important. Better navigation can also help clinicians reach small or anatomically difficult lesions that may otherwise require more invasive approaches.

 

By Imaging Modality

CT and Cone-Beam CT Guidance

CT and cone-beam CT are the leading modalities, representing approximately USD 2.54 billion in 2025. Their dominance reflects broad use in radiation therapy, interventional oncology, lung biopsy, abdominal tumor ablation and stereotactic treatment.

CBCT is expected to gain particular strategic importance as reconstruction quality improves. Treatment-room imaging that approaches diagnostic visualization can enable adaptive treatment without moving patients between departments.

MRI Guidance

MRI-guided oncology devices represented approximately USD 1.43 billion in 2025. MRI is particularly valuable where soft-tissue differentiation is critical, including prostate, liver, brain and pelvic oncology.

Capital intensity and workflow complexity have historically restricted adoption, but MRI guidance offers a strong clinical proposition for precision treatment. MRI-compatible instruments, real-time treatment monitoring and automated image processing should support above-market growth.

Ultrasound Guidance

Ultrasound-guided systems and devices represented approximately USD 1.10 billion in 2025. Ultrasound is widely accessible, portable, radiation-free and useful for biopsy, liver intervention, prostate procedures and selected ablative therapies.

The modality is also central to focused-ultrasound and histotripsy platforms, giving ultrasound a role not only as an imaging method but also as a therapeutic energy source.

Fluoroscopy and Angiography Guidance

Fluoroscopy and angiography-related oncology guidance represented approximately USD 1.37 billion in 2025. These systems are essential in embolization, catheter-based liver therapy, vascular access and several targeted treatment procedures.

The segment is closely tied to interventional radiology capital investment. Hospitals with large oncology referral networks are increasingly evaluating angiography suites according to oncology utilization as well as cardiovascular and neurovascular demand.

PET, Optical and Other Hybrid Guidance

PET-informed, optical, surface-imaging and hybrid guidance technologies represented approximately USD 0.82 billion in 2025. These technologies are particularly valuable for tumor localization, metabolic targeting, radiation planning and non-ionizing patient-position monitoring.

The category remains smaller than CT or MRI but has significant strategic relevance because multimodal information can improve treatment planning and target definition.

 

By Application

Prostate Cancer

Prostate cancer represents one of the largest application markets, generating an estimated USD 1.46 billion in 2025. Approximately 313,780 new U.S. prostate cancers were expected in 2025. Image-guided radiotherapy, MRI-guided biopsy, brachytherapy, focused ultrasound and focal ablation all contribute to device demand.

The movement toward shorter radiation courses and focal treatment will increase the importance of accurate localization, particularly because the prostate can shift with bladder and rectal filling.

Lung Cancer

Lung cancer accounted for approximately USD 1.39 billion in 2025. With roughly 226,650 new lung and bronchus cancers estimated nationally in 2025, the application supports substantial demand for image-guided biopsy, SBRT, ablation and respiratory motion management.

Growth is also supported by improved screening, which can identify smaller lesions that may be candidates for stereotactic or minimally invasive focal treatment.

Liver Cancer and Hepatic Metastases

Liver oncology represented approximately USD 1.21 billion in 2025. Importantly, the commercial opportunity extends beyond primary liver cancer because the liver is a common site of metastatic disease.

Image-guided microwave ablation, cryoablation, radiofrequency ablation, histotripsy and catheter-directed embolization are expanding the focal treatment toolkit. Liver intervention is consequently one of the most important arenas for interventional oncology innovation.

Breast Cancer

Breast cancer generated approximately USD 0.96 billion in image-guided oncology device revenue in 2025. Approximately 316,950 invasive female breast cancers were expected nationally during the year.

Image guidance is important in biopsy, lesion localization, radiation setup and selected focal treatments. Surface-guided radiation therapy has gained particular relevance in breast cancer because precise patient positioning can support techniques designed to limit dose to surrounding organs.

Brain and Central Nervous System Tumors

Brain and CNS applications represented approximately USD 0.89 billion in 2025. Stereotactic radiosurgery, MRI-guided laser ablation, neuronavigation, stereotactic biopsy and high-precision radiation depend heavily on imaging accuracy.

Although the patient population is smaller than breast or prostate cancer, procedure value is high because treatment requires sophisticated equipment and multidisciplinary specialist teams.

Kidney Cancer and Other Solid Tumors

Kidney and other oncology applications accounted for approximately USD 1.35 billion in 2025. Renal tumors are particularly relevant for image-guided cryoablation and thermal ablation, especially in patients for whom nephron-preserving treatment is desirable.

Other important applications include bone metastases, pancreatic tumors, head and neck cancers, gynecologic cancers and selected soft-tissue tumors.

 

By End User

Hospitals and Integrated Health Systems

Hospitals and integrated delivery networks are the dominant end users, representing approximately USD 3.55 billion in 2025. They purchase high-value linacs, CT and MRI systems, angiography suites, ablation equipment, navigation technology and recurring procedure devices.

Large IDNs increasingly standardize oncology technology across multiple campuses. Manufacturers capable of enterprise contracting, fleet management, service guarantees and software interoperability are therefore positioned more favorably than vendors competing solely on individual system specifications.

Comprehensive Cancer Centers and Specialty Oncology Networks

Comprehensive cancer centers accounted for approximately USD 1.35 billion in 2025. These organizations tend to maintain high cancer case volumes and may support specialized programs in stereotactic radiotherapy, proton therapy, interventional oncology and adaptive radiation treatment.

Their purchasing priorities emphasize clinical differentiation and referral capture as much as acquisition price.

Radiation Oncology Centers

Hospital-affiliated and freestanding radiation oncology centers represented approximately USD 1.16 billion in 2025. Replacement cycles, imaging upgrades, patient-positioning systems and treatment planning integration are major expenditure areas.

These buyers are especially sensitive to daily patient throughput because equipment utilization directly affects treatment capacity and financial performance.

Academic and Research Medical Centers

Academic medical centers accounted for approximately USD 0.72 billion in 2025 and exert influence greater than their direct market share. They are important early adopters of adaptive radiotherapy, novel ablation, robotics, MRI-guided intervention and clinical trial technologies.

Successful adoption in these institutions often creates clinical evidence, specialist training and referral patterns that support later community-market penetration.

Ambulatory and Specialty Procedure Centers

Ambulatory and specialty oncology procedure settings represented approximately USD 0.48 billion in 2025. The segment remains smaller because highly complex image-guided oncology procedures require substantial imaging and emergency-support infrastructure.

However, growth is expected as selected biopsy, ablation and lower-acuity interventions migrate toward efficient outpatient settings.

 

Regional Insights: Where the Market is Growing Fastest

The U.S. Image-Guided Oncology Devices Market is geographically segmented into the South, West, Northeast and Midwest. Regional performance is driven by cancer incidence, population aging, oncology referral density, hospital consolidation, radiation oncology capacity, academic medical center concentration, proton therapy availability and investment in interventional oncology.

The South represents the largest regional market, while the West is expected to post the fastest growth through 2035. The Northeast remains a premium technology and clinical-trial market, while the Midwest provides a substantial installed base of mature hospital and cancer-treatment infrastructure.

South

The South accounted for an estimated USD 2.47 billion in 2025, representing approximately 34% of the U.S. market. The region includes Texas, Florida, Georgia, North Carolina, South Carolina, Virginia, Maryland, Delaware, Tennessee, Kentucky, West Virginia, Alabama, Mississippi, Arkansas, Louisiana, Oklahoma and the District of Columbia within the commercial regional framework used for this analysis.

Texas and Florida are the principal state markets. Texas alone was expected to record approximately 150,870 new cancer cases in 2025, while Florida was expected to record approximately 171,960 cases. These volumes create substantial demand for radiation oncology infrastructure, advanced diagnostic-to-treatment pathways, interventional oncology and high-throughput cancer facilities.

Texas combines a large population with internationally recognized oncology institutions, particularly in Houston, as well as expanding cancer programs in Dallas-Fort Worth, Austin and San Antonio. The state is attractive for image-guided intervention because major providers can aggregate enough cancer volume to justify specialized capital platforms and dedicated interventional oncology programs.

Florida’s market is strongly influenced by its older population. The state has significant demand for prostate, lung, breast and other cancers common in older adults, supporting image-guided radiation, stereotactic treatment and minimally invasive focal therapy.

North Carolina represented approximately 71,320 expected new cancer cases in 2025 and has a strong network of academic and regional cancer programs. Georgia, Tennessee and Virginia are also important growth states because of expanding metropolitan populations and health-system investment.

Alabama, Mississippi, Kentucky, Louisiana, Arkansas, West Virginia and Oklahoma carry meaningful cancer burdens but have less uniform access to advanced oncology infrastructure. For device manufacturers, these states represent an opportunity for hub-and-spoke cancer models, teleplanning, simplified treatment workflows and equipment that can operate efficiently in regional referral hospitals.

The South is projected to expand from approximately USD 2.47 billion in 2025 to USD 6.78 billion by 2035, representing an implied CAGR of approximately 10.6%. Population growth, rising cancer incidence, hospital expansion and increasing availability of advanced oncology services will sustain regional leadership.

West

The West generated approximately USD 1.80 billion in 2025 and is projected to be the fastest-growing U.S. region, reaching approximately USD 5.37 billion by 2035.

The regional market includes California, Washington, Oregon, Arizona, Nevada, Colorado, Utah, New Mexico, Idaho, Montana, Wyoming, Alaska and Hawaii.

California is the largest state-level market in the region and one of the most strategically important oncology markets nationally. Approximately 199,980 new cancers were expected in California during 2025, the largest state total in the country. California also combines major academic health systems with a dense medical technology, artificial intelligence and life-science ecosystem.

This environment favors early adoption of adaptive radiotherapy, AI-assisted treatment planning, robotic intervention and advanced imaging. The state also provides a large referral base for proton therapy and specialized stereotactic treatment.

Arizona is another important growth state, with approximately 42,560 new cancer cases estimated in 2025. Population migration and aging are increasing demand for oncology capacity. Nevada and Utah similarly benefit from demographic expansion, while Colorado maintains a sophisticated provider network and strong adoption of advanced medical technologies.

Washington and Oregon support significant cancer treatment infrastructure across major metropolitan systems. These states are particularly attractive for integrated imaging and digital oncology solutions because large provider organizations can deploy technology across multiple facilities.

Smaller Western states create a different market opportunity. Montana, Wyoming, Idaho, Alaska and parts of New Mexico face long travel distances for specialized cancer treatment. Technologies that shorten treatment courses, support regional treatment centers or enable remote planning can therefore generate disproportionate clinical value.

The West is expected to expand at an implied CAGR of approximately 11.6% from 2026 to 2035, gaining national market share as oncology becomes increasingly software-enabled, adaptive and precision-guided.

Northeast

The Northeast accounted for approximately USD 1.62 billion in 2025 and is projected to reach approximately USD 4.04 billion by 2035.

The region includes New York, Pennsylvania, New Jersey, Massachusetts, Connecticut, Rhode Island, Maine, Vermont and New Hampshire.

New York is the dominant state market, with approximately 123,430 new cancer cases estimated in 2025. Its large population, dense hospital infrastructure and concentration of tertiary oncology programs generate significant demand for high-end image-guided systems.

Pennsylvania represented approximately 90,240 new cancer cases in 2025 and has substantial academic and community oncology infrastructure. Philadelphia and Pittsburgh both function as major regional referral centers for radiation oncology, surgical oncology and interventional treatment.

Massachusetts has a smaller population but disproportionate strategic importance because of Boston’s concentration of academic hospitals, oncology research programs, biotechnology companies and early-stage medical technology development. New oncology technologies evaluated in Massachusetts institutions can influence broader U.S. adoption.

New Jersey and Connecticut provide attractive markets because of high healthcare utilization and proximity to major academic centers. Maine, Vermont, New Hampshire and Rhode Island are smaller markets where equipment utilization and referral economics are particularly important procurement considerations.

The Northeast tends to have rigorous value-analysis processes. Hospitals often require strong clinical evidence before changing established oncology workflows, but once technology is adopted, procedure complexity and high-acuity referral patterns can support premium equipment utilization.

The region is expected to grow at approximately 9.6% annually, slower than the West but remaining highly important for advanced technology launches and clinical evidence generation.

Midwest

The Midwest represented an estimated USD 1.37 billion in 2025 and is projected to reach approximately USD 3.20 billion by 2035.

The region includes Illinois, Ohio, Michigan, Minnesota, Indiana, Wisconsin, Missouri, Iowa, Kansas, Nebraska, North Dakota and South Dakota.

Illinois and Ohio are the largest regional markets. Illinois was expected to record approximately 78,870 new cancer cases in 2025, while Ohio was expected to record approximately 77,010 cases. Chicago, Cleveland, Columbus and Cincinnati support substantial cancer referral networks and sophisticated radiation and interventional oncology capabilities.

Michigan also maintains a large oncology treatment base, while Minnesota has unusual strategic significance because of its medtech ecosystem and strong academic healthcare institutions. Wisconsin, Indiana and Missouri provide substantial community-hospital and regional cancer-center demand.

Iowa, Kansas, Nebraska, North Dakota and South Dakota have smaller populations and lower total procedure volumes, but oncology access remains strategically important because many patients live far from tertiary centers. Hypofractionated radiation, efficient stereotactic platforms and technologies that allow more treatment to remain within regional health systems may therefore have strong economic value.

The Midwest is expected to record an implied CAGR of approximately 8.9% through 2035. Although growth will trail the South and West, the region’s large installed equipment base creates significant replacement and modernization opportunities.

 

Key Market Players

The U.S. Image-Guided Oncology Devices Competitive Landscape is characterized by large imaging and radiation oncology platform companies at the top of the market, surrounded by specialized innovators in ablation, robotics, navigation, proton therapy and motion management.

Competition is increasingly ecosystem-based. Leading companies compete not merely on an imaging system or treatment device but on their ability to connect treatment planning, imaging, navigation, delivery, quality assurance and oncology data. Service contracts, installed-base compatibility, physician training, regulatory evidence and hospital enterprise agreements strongly influence competitive positioning.

Some of the key players operating in or addressing the U.S. Image-Guided Oncology Devices Market include:

Siemens Healthineers / Varian
Elekta
Accuray Incorporated
GE HealthCare
Philips
Canon Medical Systems USA
United Imaging Healthcare
IBA
Mevion Medical Systems
Brainlab
C-RAD
Vision RT
Medtronic
Boston Scientific Corporation
Johnson & Johnson MedTech / Ethicon
AngioDynamics
Merit Medical Systems
Terumo Interventional Systems
Cook Medical
HistoSonics
Profound Medical
INSIGHTEC
Monteris Medical
IceCure Medical
Quantum Surgical

Siemens Healthineers and Varian have one of the broadest strategic positions because they connect diagnostic imaging, radiation oncology, treatment planning and image-guided intervention. Elekta and Accuray remain significant competitors in high-precision radiation treatment, while GE HealthCare and Philips have extensive imaging and image-guided therapy infrastructures.

Medtronic, Boston Scientific, Johnson & Johnson, AngioDynamics, Merit Medical, Terumo and Cook Medical participate more heavily in interventional oncology and procedure-specific technologies. Their opportunity is tied to recurring device utilization as ablation and embolization procedure volumes expand.

HistoSonics, Profound Medical, INSIGHTEC, Monteris Medical, IceCure and Quantum Surgical represent the specialized innovation layer. These companies are addressing focal therapy through histotripsy, ultrasound, MRI-guided treatment, laser ablation, cryoablation and robotic assistance.

Market share through 2035 will be influenced by FDA clearances, clinical evidence, integration with existing hospital systems, reimbursement, treatment throughput, physician learning curves and the ability to reduce the total cost of an oncology episode. Companies that can turn sophisticated guidance technology into repeatable clinical workflow will have the strongest competitive position.

 

Recent Developments

Recent U.S. market developments demonstrate that image-guided oncology innovation is broadening beyond conventional radiation equipment.

In October 2025, the FDA granted De Novo authorization for the IceCure ProSense System as a cryoablation device for local treatment of selected low-risk breast cancer. The development is strategically important because it extends image-guided focal ablation further into breast oncology, an area historically dominated by surgery and radiation.

MRI-guided treatment also continued advancing. In May 2025, the FDA cleared the Medtronic Visualase V2 MRI-guided Laser Ablation System, strengthening the role of MRI thermography and minimally invasive laser therapy in neurological applications.

HistoSonics remains important to the market’s shift toward non-thermal focal therapy. Its Edison System established the U.S. regulatory category for focused-ultrasound mechanical tissue ablation, while the FDA subsequently cleared the HistoSonics Planning Tool in May 2026. Planning software is important because accurate image-based treatment mapping is essential if histotripsy is to scale from specialized centers toward standardized procedural programs.

Siemens Healthineers also expanded ablation workflow capability. The FDA cleared myAblation Guide VB80A in August 2024 and a newer VC10A version in June 2026, reflecting increasing regulatory and commercial activity around software that supports image-based ablation planning and evaluation.

Radiation oncology software continues to evolve in parallel. Varian received U.S. clearance for updated treatment planning, radiation management and image-suite technologies during 2024–2026. These developments reinforce the competitive shift from standalone linear accelerator hardware toward integrated image, planning and treatment-management ecosystems.

Proton therapy capacity has continued expanding. The U.S. had 46 operating proton centers at the end of 2024, increasing to approximately 50 operating facilities by 2026. The evolution toward more compact facilities and single-room configurations can broaden the number of institutions able to consider particle therapy.

The broader strategic direction is clear: image guidance is moving closer to therapy delivery. Planning, imaging, navigation and treatment are progressively being combined into a single workflow. That integration will be one of the defining competitive forces in the U.S. market through 2035.

 

Conclusion

The U.S. Image-Guided Oncology Devices Market Size & Share is positioned to expand from approximately USD 7.26 billion in 2025 to USD 19.39 billion by 2035, reflecting a 10.32% CAGR during 2026–2035.

The market’s growth is supported by a combination of more than two million annual cancer diagnoses, increasing cancer survivorship, an aging U.S. population, continued radiation therapy utilization and expanding demand for minimally invasive treatment.

The most important change, however, is not cancer volume alone. The fundamental growth engine is the transition toward more precise oncology. Tumors are increasingly treated using technologies designed to account for anatomy, motion, biological information and treatment-response changes in real time or near real time.

Image-guided radiation therapy will remain the largest revenue category, but faster percentage growth is expected in robotic navigation, adaptive treatment, MRI-guided intervention, image-guided ablation and novel focal therapies. Histotripsy, cryoablation, microwave ablation and MRI-guided treatment will expand the addressable opportunity for patients who may benefit from nonsurgical local treatment.

Hospitals will increasingly judge these technologies according to procedure economics. Equipment that enables shorter treatments, higher daily throughput, reduced physician labor, outpatient migration or expansion of treatable patient populations will be favored over technology that provides imaging improvements without corresponding workflow value.

Regional opportunity will be led by the South, supported by the scale of Texas, Florida and fast-growing Southeastern markets. The West is expected to record the fastest growth because of California’s technology ecosystem, population growth in Arizona and Nevada, and strong adoption of advanced oncology workflows. The Northeast will remain critical for clinical evidence and premium technology adoption, while the Midwest will provide a substantial replacement and modernization market.

At the state level, California, Florida, Texas, New York, Pennsylvania, Illinois, Ohio, North Carolina, Georgia, Arizona, Massachusetts and Michigan will remain especially important markets for manufacturers seeking national oncology-device penetration.

For medical device companies, investors, hospital systems and market-entry teams, the central question is no longer whether image guidance will remain important to U.S. oncology. It is where image guidance becomes sufficiently integrated with treatment delivery to alter the economics of cancer care.

Companies capable of connecting high-quality visualization with accurate navigation, efficient treatment delivery, clinical evidence and measurable hospital productivity will define the next decade of the U.S. Image-Guided Oncology Devices Market.

 

TABLE OF CONTENT

1. U.S. Image-Guided Oncology Devices Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Analytical Frameworks & Forecasting Models
1.3.6. Data Validation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. Image-Guided Oncology Device Manufacturers
1.6.2. Imaging System and Oncology Technology Suppliers
1.6.3. Radiation Oncology Equipment Manufacturers
1.6.4. Interventional Oncology and Tumor Ablation Device Companies
1.6.5. Hospitals and Integrated Health Systems
1.6.6. Comprehensive Cancer Centers and Radiation Oncology Networks
1.6.7. Academic Medical Centers and Clinical Research Institutions
1.6.8. Group Purchasing Organizations, Distributors, and Service Providers
1.6.9. Payers, Regulators, and Clinical Decision-Makers

What this section provides: This section establishes the market boundary, study scope, methodology, assumptions, and stakeholder ecosystem used to measure and validate the U.S. Image-Guided Oncology Devices Market.

2. U.S. Image-Guided Oncology Devices Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. U.S. Cancer Treatment Infrastructure Snapshot
2.8. Image-Guided Oncology Procedure Adoption Snapshot
2.9. High-Growth Opportunity Areas
2.10. Key Investment and Commercialization Themes

What this section provides: This section gives decision-makers a concise view of market size, growth trajectory, technology adoption, clinical demand, competitive intensity, and the highest-priority commercial opportunities through 2035.

3. U.S. Image-Guided Oncology Devices Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. Rising U.S. Cancer Incidence and Cancer Survivorship
3.1.2. Increasing Adoption of Precision and Image-Guided Cancer Treatment
3.1.3. Growth in Stereotactic Radiation Therapy and Hypofractionated Treatment
3.1.4. Expansion of Interventional Oncology and Minimally Invasive Tumor Ablation
3.1.5. Growing Demand for Adaptive Radiation Therapy
3.1.6. Hospital Radiation Oncology and Interventional Suite Modernization
3.1.7. Increasing Need for Accurate Tumor Localization and Motion Management
3.1.8. Expansion of Outpatient and Organ-Preserving Oncology Treatment

3.2. Restraints and Their Impact Analysis
3.2.1. High Capital Cost of Advanced Image-Guided Oncology Systems
3.2.2. Complex Installation and Infrastructure Requirements
3.2.3. Reimbursement and Capital Budget Constraints
3.2.4. Long Equipment Replacement Cycles
3.2.5. Specialist Training and Workforce Requirements
3.2.6. Technology Integration and Interoperability Challenges

3.3. Opportunities and Their Impact Analysis
3.3.1. Adaptive Radiotherapy Expansion
3.3.2. MRI-Guided Oncology Treatment
3.3.3. Robotic and Navigated Tumor Intervention
3.3.4. Histotripsy and Non-Thermal Tumor Ablation
3.3.5. Image-Guided Cryoablation and Microwave Ablation
3.3.6. AI-Assisted Treatment Planning and Image Registration
3.3.7. Surface-Guided Radiation Therapy
3.3.8. Expansion of Proton and Particle Therapy Infrastructure

3.4. Challenges and Their Impact Analysis
3.4.1. Clinical Evidence Requirements for Novel Oncology Technologies
3.4.2. Workflow Complexity and Procedure Time
3.4.3. Hospital Value Analysis Committee Scrutiny
3.4.4. Competition Between Capital Equipment Priorities
3.4.5. Cybersecurity and Oncology Data Integration Risk

3.5. Patent & Innovation Analysis, 2021–2025
3.6. Image-Guided Oncology Clinical Workflow Economics Analysis
3.7. Hospital Capital Procurement Behavior Analysis
3.8. Radiation Oncology Equipment Replacement Cycle Analysis
3.9. Interventional Oncology Procedure Economics Analysis

What this section provides: This section explains the clinical, commercial, reimbursement, technological, and operational forces influencing image-guided oncology device adoption and helps clients evaluate opportunity against implementation risk.

4. U.S. Image-Guided Oncology Devices Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal

4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers
4.2.3. Bargaining Power of Suppliers
4.2.4. Substitution Risk
4.2.5. Competitive Rivalry

4.3. Pricing Trend Analysis by Region, 2025–2035
4.4. Value Chain & Supply Chain Analysis
4.5. Capital Equipment Versus Recurring Consumables Revenue Analysis
4.6. Impact of Digitalization on Image-Guided Oncology Workflows
4.7. Artificial Intelligence and Automation Landscape
4.8. Application & Innovation Landscape
4.9. FDA Regulatory Framework Analysis
4.10. CMS Reimbursement and Coverage Landscape
4.11. Radiation Oncology Reimbursement Environment
4.12. Interventional Oncology Reimbursement Environment
4.13. Import/Export Restrictions & Tariff Impact
4.14. Government Cancer Programs and Public Health Initiatives
4.15. Impact of Escalating Geopolitical Tensions
4.16. Hospital Value Analysis Committee Decision Framework
4.17. Technology Assessment and Capital Budget Approval Framework
4.18. Installed Base, Replacement, and Upgrade Cycle Analysis

What this section provides: This section gives clients a comprehensive view of regulation, reimbursement, pricing, technology evolution, supply chains, capital equipment economics, and institutional purchasing factors influencing the U.S. market.

5. U.S. Image-Guided Oncology Devices Market – By Product Category

5.1. Overview
5.1.1. Segment Share Analysis, By Product Category, 2025 & 2035 (%)
5.1.2. Image-Guided Radiation Therapy Systems
5.1.2.1. Image-Enabled Linear Accelerator Systems
5.1.2.2. Cone-Beam CT-Guided Radiation Therapy Systems
5.1.2.3. MRI-Guided Radiation Therapy Systems
5.1.2.4. Stereotactic Radiosurgery Systems
5.1.2.5. Stereotactic Body Radiation Therapy Systems
5.1.2.6. Image-Guided Brachytherapy Systems
5.1.2.7. Surface and Patient Position Verification Systems

5.1.3. Image-Guided Tumor Ablation Systems
5.1.3.1. Microwave Ablation Systems
5.1.3.2. Radiofrequency Ablation Systems
5.1.3.3. Cryoablation Systems
5.1.3.4. Laser Ablation Systems
5.1.3.5. High-Intensity Focused Ultrasound Systems
5.1.3.6. Irreversible Electroporation Systems
5.1.3.7. Histotripsy Systems

5.1.4. Oncology Navigation and Robotic Guidance Systems
5.1.4.1. CT-Guided Navigation Systems
5.1.4.2. Electromagnetic Navigation Systems
5.1.4.3. Optical Tracking and Navigation Systems
5.1.4.4. Robotic Needle Guidance Systems
5.1.4.5. Stereotactic Navigation Platforms

5.1.5. Image-Guided Embolization and Targeted Therapy Delivery Devices
5.1.5.1. Microcatheters
5.1.5.2. Embolization Delivery Catheters
5.1.5.3. Guidewires and Access Devices
5.1.5.4. Targeted Delivery Platforms
5.1.5.5. Procedure-Specific Interventional Oncology Accessories

5.1.6. Image-Guided Biopsy, Localization and Procedure Planning Devices
5.1.6.1. Stereotactic Biopsy Systems
5.1.6.2. Image-Guided Biopsy Needles and Instruments
5.1.6.3. Tumor Localization Devices
5.1.6.4. Fiducial Markers
5.1.6.5. Treatment Planning and Procedure Guidance Devices

What this section provides: This section identifies the product categories expected to generate the largest revenue pools and highlights where radiation therapy, ablation, robotic guidance, targeted delivery, and precision localization technologies are creating the strongest growth opportunities.

6. U.S. Image-Guided Oncology Devices Market – By Imaging Modality

6.1. Overview
6.1.1. Segment Share Analysis, By Imaging Modality, 2025 & 2035 (%)

6.1.2. CT and Cone-Beam CT Guidance
6.1.2.1. Conventional CT Guidance
6.1.2.2. Cone-Beam CT Guidance
6.1.2.3. CT Fluoroscopy Guidance
6.1.2.4. CT-Based Treatment Planning and Navigation

6.1.3. MRI Guidance
6.1.3.1. MRI-Guided Radiation Therapy
6.1.3.2. MRI-Guided Tumor Ablation
6.1.3.3. MRI-Guided Biopsy and Intervention
6.1.3.4. MRI Thermometry and Treatment Monitoring

6.1.4. Ultrasound Guidance
6.1.4.1. Conventional Ultrasound Guidance
6.1.4.2. 3D and 4D Ultrasound Guidance
6.1.4.3. Fusion Ultrasound Guidance
6.1.4.4. Focused Ultrasound Guidance
6.1.4.5. Histotripsy Guidance

6.1.5. Fluoroscopy and Angiography Guidance
6.1.5.1. Conventional Fluoroscopy Guidance
6.1.5.2. Digital Subtraction Angiography
6.1.5.3. Cone-Beam Angiographic Guidance
6.1.5.4. Interventional Oncology Suite Guidance

6.1.6. PET, Optical and Other Hybrid Guidance
6.1.6.1. PET/CT-Informed Guidance
6.1.6.2. PET/MRI-Informed Guidance
6.1.6.3. Optical Surface Guidance
6.1.6.4. Multimodality Fusion Guidance
6.1.6.5. Other Emerging Hybrid Imaging Technologies

What this section provides: This section evaluates how CT, MRI, ultrasound, angiography, PET-derived, optical, and hybrid imaging technologies influence procedural precision, workflow economics, treatment selection, and future technology adoption.

7. U.S. Image-Guided Oncology Devices Market – By Application

7.1. Overview
7.1.1. Segment Share Analysis, By Application, 2025 & 2035 (%)

7.1.2. Prostate Cancer
7.1.2.1. Image-Guided Radiation Therapy
7.1.2.2. MRI-Guided Biopsy
7.1.2.3. Brachytherapy Guidance
7.1.2.4. Focal Tumor Ablation

7.1.3. Lung Cancer
7.1.3.1. Stereotactic Body Radiation Therapy
7.1.3.2. Image-Guided Biopsy
7.1.3.3. Percutaneous Tumor Ablation
7.1.3.4. Respiratory Motion Management

7.1.4. Liver Cancer and Hepatic Metastases
7.1.4.1. Microwave Ablation
7.1.4.2. Radiofrequency Ablation
7.1.4.3. Cryoablation
7.1.4.4. Histotripsy
7.1.4.5. Image-Guided Embolization
7.1.4.6. Stereotactic Radiation Therapy

7.1.5. Breast Cancer
7.1.5.1. Image-Guided Biopsy and Localization
7.1.5.2. Image-Guided Radiation Therapy
7.1.5.3. Surface-Guided Radiation Therapy
7.1.5.4. Image-Guided Cryoablation

7.1.6. Brain and Central Nervous System Tumors
7.1.6.1. Stereotactic Radiosurgery
7.1.6.2. MRI-Guided Laser Ablation
7.1.6.3. Stereotactic Biopsy
7.1.6.4. Image-Guided Neurosurgical Oncology

7.1.7. Kidney Cancer
7.1.7.1. Cryoablation
7.1.7.2. Microwave Ablation
7.1.7.3. Radiofrequency Ablation
7.1.7.4. CT- and Ultrasound-Guided Intervention

7.1.8. Other Solid Tumors
7.1.8.1. Bone and Soft-Tissue Tumors
7.1.8.2. Pancreatic Cancer
7.1.8.3. Head and Neck Cancer
7.1.8.4. Gynecologic Cancer
7.1.8.5. Colorectal and Metastatic Tumors

What this section provides: This section helps clients identify cancer indications generating the strongest demand for precision radiation, image-guided biopsy, tumor ablation, robotic navigation, and other image-guided therapeutic technologies.

8. U.S. Image-Guided Oncology Devices Market – By End User

8.1. Overview
8.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)

8.1.2. Hospitals and Integrated Health Systems
8.1.2.1. Large Integrated Delivery Networks
8.1.2.2. Tertiary and Quaternary Hospitals
8.1.2.3. Community Hospital Oncology Programs

8.1.3. Comprehensive Cancer Centers and Specialty Oncology Networks
8.1.3.1. NCI-Designated and Comprehensive Cancer Centers
8.1.3.2. Regional Cancer Networks
8.1.3.3. Specialty Oncology Hospitals

8.1.4. Radiation Oncology Centers
8.1.4.1. Hospital-Affiliated Radiation Oncology Centers
8.1.4.2. Freestanding Radiation Oncology Centers
8.1.4.3. Stereotactic Radiation Centers
8.1.4.4. Proton Therapy Centers

8.1.5. Academic and Research Medical Centers
8.1.5.1. University Hospitals
8.1.5.2. Clinical Trial Centers
8.1.5.3. Translational Oncology Research Institutions

8.1.6. Ambulatory and Specialty Procedure Centers
8.1.6.1. Interventional Radiology Centers
8.1.6.2. Ambulatory Oncology Procedure Centers
8.1.6.3. Image-Guided Biopsy and Ablation Centers

What this section provides: This section explains which U.S. care settings are expected to drive capital equipment purchases, procedural consumable utilization, technology adoption, replacement cycles, and premium image-guided oncology workflows.

9. U.S. Image-Guided Oncology Devices Market – By Geography
9.1. Introduction

9.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
9.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
9.1.3. Regional Cancer Incidence and Treatment Volume Analysis
9.1.4. Regional Radiation Oncology Infrastructure Analysis
9.1.5. Regional Interventional Oncology Infrastructure Analysis
9.1.6. Regional Reimbursement and Procurement Dynamics
9.1.7. Regional Technology Adoption and Capital Replacement Analysis

9.2. West Region

9.2.1. Regional Overview & Trends
9.2.2. West Region Key Manufacturers, Cancer Centers, and Procurement Ecosystem
9.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
9.2.4. West Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.5. West Region Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.2.6. West Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.7. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.2.8. California

9.2.8.1. Overview
9.2.8.2. California Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.8.3. California Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.2.8.4. California Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.8.5. California Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.2.9. Washington

9.2.9.1. Overview
9.2.9.2. Washington Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.9.3. Washington Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.2.9.4. Washington Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.9.5. Washington Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.2.10. Arizona

9.2.10.1. Overview
9.2.10.2. Arizona Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.10.3. Arizona Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.2.10.4. Arizona Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.10.5. Arizona Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.2.11. Colorado

9.2.11.1. Overview
9.2.11.2. Colorado Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.11.3. Colorado Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.2.11.4. Colorado Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.11.5. Colorado Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.2.12. Oregon

9.2.12.1. Overview
9.2.12.2. Oregon Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.12.3. Oregon Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.2.12.4. Oregon Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.12.5. Oregon Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.2.13. Utah

9.2.13.1. Overview
9.2.13.2. Utah Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.13.3. Utah Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.2.13.4. Utah Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.13.5. Utah Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.2.14. Nevada

9.2.14.1. Overview
9.2.14.2. Nevada Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.14.3. Nevada Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.2.14.4. Nevada Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.14.5. Nevada Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.2.15. New Mexico

9.2.15.1. Overview
9.2.15.2. New Mexico Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.15.3. New Mexico Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.2.15.4. New Mexico Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.15.5. New Mexico Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.2.16. Idaho

9.2.16.1. Overview
9.2.16.2. Idaho Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.16.3. Idaho Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.2.16.4. Idaho Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.16.5. Idaho Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.2.17. Montana

9.2.17.1. Overview
9.2.17.2. Montana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.17.3. Montana Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.2.17.4. Montana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.17.5. Montana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.2.18. Wyoming

9.2.18.1. Overview
9.2.18.2. Wyoming Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.18.3. Wyoming Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.2.18.4. Wyoming Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.18.5. Wyoming Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.2.19. Alaska

9.2.19.1. Overview
9.2.19.2. Alaska Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.19.3. Alaska Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.2.19.4. Alaska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.19.5. Alaska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.2.20. Hawaii

9.2.20.1. Overview
9.2.20.2. Hawaii Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.20.3. Hawaii Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.2.20.4. Hawaii Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.2.20.5. Hawaii Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.3. Northeast Region

9.3.1. Regional Overview & Trends
9.3.2. Northeast Region Key Manufacturers, Cancer Centers, and Procurement Ecosystem
9.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
9.3.4. Northeast Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.5. Northeast Region Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.3.6. Northeast Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.7. Northeast Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.3.8. New York

9.3.8.1. Overview
9.3.8.2. New York Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.8.3. New York Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.3.8.4. New York Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.8.5. New York Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.3.9. Massachusetts

9.3.9.1. Overview
9.3.9.2. Massachusetts Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.9.3. Massachusetts Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.3.9.4. Massachusetts Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.9.5. Massachusetts Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.3.10. New Jersey

9.3.10.1. Overview
9.3.10.2. New Jersey Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.10.3. New Jersey Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.3.10.4. New Jersey Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.10.5. New Jersey Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.3.11. Pennsylvania

9.3.11.1. Overview
9.3.11.2. Pennsylvania Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.11.3. Pennsylvania Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.3.11.4. Pennsylvania Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.11.5. Pennsylvania Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.3.12. Connecticut

9.3.12.1. Overview
9.3.12.2. Connecticut Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.12.3. Connecticut Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.3.12.4. Connecticut Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.12.5. Connecticut Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.3.13. Maine

9.3.13.1. Overview
9.3.13.2. Maine Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.13.3. Maine Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.3.13.4. Maine Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.13.5. Maine Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.3.14. Vermont

9.3.14.1. Overview
9.3.14.2. Vermont Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.14.3. Vermont Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.3.14.4. Vermont Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.14.5. Vermont Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.3.15. New Hampshire

9.3.15.1. Overview
9.3.15.2. New Hampshire Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.15.3. New Hampshire Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.3.15.4. New Hampshire Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.15.5. New Hampshire Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.3.16. Rhode Island

9.3.16.1. Overview
9.3.16.2. Rhode Island Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.16.3. Rhode Island Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.3.16.4. Rhode Island Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.16.5. Rhode Island Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.3.17. Delaware

9.3.17.1. Overview
9.3.17.2. Delaware Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.3.17.3. Delaware Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.3.17.4. Delaware Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.3.17.5. Delaware Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4. South Region

9.4.1. Regional Overview & Trends
9.4.2. South Region Key Manufacturers, Cancer Centers, and Procurement Ecosystem
9.4.3. South Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
9.4.4. South Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.5. South Region Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.4.6. South Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.7. South Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4.8. Texas

9.4.8.1. Overview
9.4.8.2. Texas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.8.3. Texas Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.4.8.4. Texas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.8.5. Texas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4.9. Florida

9.4.9.1. Overview
9.4.9.2. Florida Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.9.3. Florida Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.4.9.4. Florida Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.9.5. Florida Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4.10. Georgia

9.4.10.1. Overview
9.4.10.2. Georgia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.10.3. Georgia Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.4.10.4. Georgia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.10.5. Georgia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4.11. North Carolina

9.4.11.1. Overview
9.4.11.2. North Carolina Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.11.3. North Carolina Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.4.11.4. North Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.11.5. North Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4.12. Tennessee

9.4.12.1. Overview
9.4.12.2. Tennessee Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.12.3. Tennessee Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.4.12.4. Tennessee Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.12.5. Tennessee Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4.13. South Carolina

9.4.13.1. Overview
9.4.13.2. South Carolina Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.13.3. South Carolina Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.4.13.4. South Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.13.5. South Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4.14. Alabama

9.4.14.1. Overview
9.4.14.2. Alabama Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.14.3. Alabama Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.4.14.4. Alabama Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.14.5. Alabama Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4.15. Mississippi

9.4.15.1. Overview
9.4.15.2. Mississippi Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.15.3. Mississippi Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.4.15.4. Mississippi Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.15.5. Mississippi Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4.16. Louisiana

9.4.16.1. Overview
9.4.16.2. Louisiana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.16.3. Louisiana Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.4.16.4. Louisiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.16.5. Louisiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4.17. Arkansas

9.4.17.1. Overview
9.4.17.2. Arkansas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.17.3. Arkansas Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.4.17.4. Arkansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.17.5. Arkansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4.18. Kentucky

9.4.18.1. Overview
9.4.18.2. Kentucky Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.18.3. Kentucky Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.4.18.4. Kentucky Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.18.5. Kentucky Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4.19. Oklahoma

9.4.19.1. Overview
9.4.19.2. Oklahoma Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.19.3. Oklahoma Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.4.19.4. Oklahoma Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.19.5. Oklahoma Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4.20. Virginia

9.4.20.1. Overview
9.4.20.2. Virginia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.20.3. Virginia Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.4.20.4. Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.20.5. Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4.21. Maryland

9.4.21.1. Overview
9.4.21.2. Maryland Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.21.3. Maryland Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.4.21.4. Maryland Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.21.5. Maryland Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.4.22. West Virginia

9.4.22.1. Overview
9.4.22.2. West Virginia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.4.22.3. West Virginia Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.4.22.4. West Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.4.22.5. West Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.5. Midwest Region

9.5.1. Regional Overview & Trends
9.5.2. Midwest Region Key Manufacturers, Cancer Centers, and Procurement Ecosystem
9.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
9.5.4. Midwest Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.5. Midwest Region Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.5.6. Midwest Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.7. Midwest Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.5.8. Illinois

9.5.8.1. Overview
9.5.8.2. Illinois Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.8.3. Illinois Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.5.8.4. Illinois Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.8.5. Illinois Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.5.9. Ohio

9.5.9.1. Overview
9.5.9.2. Ohio Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.9.3. Ohio Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.5.9.4. Ohio Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.9.5. Ohio Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.5.10. Michigan

9.5.10.1. Overview
9.5.10.2. Michigan Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.10.3. Michigan Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.5.10.4. Michigan Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.10.5. Michigan Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.5.11. Minnesota

9.5.11.1. Overview
9.5.11.2. Minnesota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.11.3. Minnesota Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.5.11.4. Minnesota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.11.5. Minnesota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.5.12. Indiana

9.5.12.1. Overview
9.5.12.2. Indiana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.12.3. Indiana Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.5.12.4. Indiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.12.5. Indiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.5.13. Wisconsin

9.5.13.1. Overview
9.5.13.2. Wisconsin Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.13.3. Wisconsin Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.5.13.4. Wisconsin Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.13.5. Wisconsin Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.5.14. Missouri

9.5.14.1. Overview
9.5.14.2. Missouri Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.14.3. Missouri Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.5.14.4. Missouri Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.14.5. Missouri Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.5.15. Iowa

9.5.15.1. Overview
9.5.15.2. Iowa Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.15.3. Iowa Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.5.15.4. Iowa Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.15.5. Iowa Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.5.16. Kansas

9.5.16.1. Overview
9.5.16.2. Kansas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.16.3. Kansas Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.5.16.4. Kansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.16.5. Kansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.5.17. Nebraska

9.5.17.1. Overview
9.5.17.2. Nebraska Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.17.3. Nebraska Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.5.17.4. Nebraska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.17.5. Nebraska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.5.18. North Dakota

9.5.18.1. Overview
9.5.18.2. North Dakota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.18.3. North Dakota Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.5.18.4. North Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.18.5. North Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

9.5.19. South Dakota

9.5.19.1. Overview
9.5.19.2. South Dakota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.5.19.3. South Dakota Market Size and Forecast, By Imaging Modality, 2021–2035 (US$ Billion)
9.5.19.4. South Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
9.5.19.5. South Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)

What this section provides: This section delivers detailed regional and state-level intelligence across all 50 U.S. states, helping clients identify cancer-treatment hubs, image-guided oncology adoption hotspots, capital replacement opportunities, procedure-volume concentrations, and priority state-level commercialization opportunities.

10. U.S. Image-Guided Oncology Devices Market: Competitive Landscape & Company Profiles

10.1. Market Share Analysis, 2025
10.2. Competitive Benchmarking
10.2.1. Product Portfolio Breadth
10.2.2. Image-Guidance Technology Strength
10.2.3. Radiation Oncology Positioning
10.2.4. Interventional Oncology Positioning
10.2.5. Installed Base and Service Network
10.2.6. U.S. Regulatory and Commercialization Strength

10.3. Company Positioning Matrix
10.3.1. Leaders
10.3.2. Challengers
10.3.3. Innovators
10.3.4. Emerging Players

10.4. Strategic Developments Analysis
10.4.1. Product Launches
10.4.2. FDA Clearances and Approvals
10.4.3. Mergers & Acquisitions
10.4.4. Partnerships and Collaborations
10.4.5. Clinical Trials and Evidence Generation
10.4.6. U.S. Hospital and Cancer Center Installations

10.5. Company Profiles

10.5.1. Siemens Healthineers / Varian
10.5.2. Elekta
10.5.3. Accuray Incorporated
10.5.4. GE HealthCare
10.5.5. Philips
10.5.6. Canon Medical Systems USA
10.5.7. United Imaging Healthcare
10.5.8. IBA
10.5.9. Mevion Medical Systems
10.5.10. Brainlab
10.5.11. C-RAD
10.5.12. Vision RT
10.5.13. Medtronic
10.5.14. Boston Scientific Corporation
10.5.15. Johnson & Johnson MedTech / Ethicon
10.5.16. AngioDynamics
10.5.17. Merit Medical Systems
10.5.18. Terumo Interventional Systems
10.5.19. Cook Medical
10.5.20. HistoSonics
10.5.21. Profound Medical
10.5.22. INSIGHTEC
10.5.23. Monteris Medical
10.5.24. IceCure Medical
10.5.25. Quantum Surgical

Note: Each company profile will include company overview, image-guided oncology device portfolio, U.S. market strategy, product positioning, financial and commercial positioning, clinical pipeline, FDA regulatory updates, partnerships, installations, and recent developments.

What this section provides: This section gives clients competitor benchmarking, market-share visibility, portfolio positioning, innovation direction, regulatory intelligence, and strategic analysis of leading and emerging image-guided oncology device companies.

11. U.S. Image-Guided Oncology Devices Market: Future Market Outlook, 2026–2035

11.1. Scenario Analysis
11.1.1. Optimistic Scenario
11.1.2. Realistic Scenario
11.1.3. Pessimistic Scenario

11.2. Disruptive Technologies Impact
11.2.1. Adaptive Radiation Therapy
11.2.2. MRI-Guided Radiation and Ablation
11.2.3. AI-Assisted Oncology Imaging and Treatment Planning
11.2.4. Robotic CT-Guided Tumor Intervention
11.2.5. Histotripsy and Non-Thermal Focal Therapy
11.2.6. Image-Guided Cryoablation and Microwave Ablation
11.2.7. Surface-Guided Radiation Therapy
11.2.8. Proton and Particle Therapy Expansion
11.2.9. Multimodality Image Fusion and Real-Time Navigation

11.3. Emerging Business Trends
11.3.1. Shift Toward Platform-Based Oncology Ecosystems
11.3.2. Growth of Recurring Consumables Around Capital Platforms
11.3.3. Expansion of Outpatient Image-Guided Oncology
11.3.4. Enterprise Oncology Technology Contracting
11.3.5. Software and Service Revenue Expansion

11.4. Business Opportunities for Startups and Existing Players
11.5. Investment Prioritization Matrix
11.6. Technology Adoption Curve, 2026–2035
11.7. Capital Replacement Opportunity Analysis
11.8. High-Growth Product–Application Opportunity Matrix
11.9. Regional Opportunity Prioritization Matrix

What this section provides: This section prepares clients for future technology shifts, treatment workflow changes, market structure evolution, investment opportunities, and plausible adoption scenarios across the U.S. image-guided oncology ecosystem through 2035.

12. U.S. Image-Guided Oncology Devices Market: Strategic Recommendations

12.1. Recommendations for Image-Guided Oncology Device Manufacturers
12.2. Recommendations for Radiation Oncology Technology Companies
12.3. Recommendations for Interventional Oncology Device Manufacturers
12.4. Recommendations for Hospitals and Integrated Health Systems
12.5. Recommendations for Comprehensive Cancer Centers
12.6. Recommendations for Investors and Private Equity Firms
12.7. Recommendations for Distributors and Channel Partners
12.8. Recommendations for New Entrants and Startups
12.9. Go-to-Market Strategy Considerations
12.10. Product Positioning and Portfolio Expansion Guidance
12.11. FDA and Reimbursement Commercialization Considerations
12.12. U.S. State-Level Market Entry Prioritization
12.13. Strategic Partnership and Clinical Evidence Roadmap

What this section provides: This section converts market intelligence into actionable recommendations for growth planning, product positioning, market entry, capital allocation, partnership strategy, hospital commercialization, and competitive differentiation.

13. U.S. Image-Guided Oncology Devices Market: Disclaimer

13.1. Scope Limitation
13.2. Market Definition Limitation
13.3. Data Use Limitation
13.4. Forecasting Limitation
13.5. Clinical and Regulatory Information Limitation
13.6. Legal Disclaimer
13.7. Third-Party Data Disclaimer

What this section provides: This section clarifies the report’s market boundaries, methodological limitations, forecasting assumptions, data-use conditions, clinical information limitations, and applicable legal disclaimers.

 

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. Image-Guided Oncology Devices Market: Market Definition and Scope
TABLE 3: U.S. Image-Guided Oncology Devices Market: Research Methodology Framework
TABLE 4: U.S. Image-Guided Oncology Devices Market: Key Assumptions
TABLE 5: U.S. Image-Guided Oncology Devices Market: Market Ecosystem Overview
TABLE 6: U.S. Image-Guided Oncology Devices Market: Stakeholder Analysis
TABLE 7: U.S. Image-Guided Oncology Devices Market: Executive Summary Snapshot, 2025
TABLE 8: U.S. Image-Guided Oncology Devices Market: Analyst Viewpoint Summary
TABLE 9: U.S. Image-Guided Oncology Devices Market: Market Attractiveness Index
TABLE 10: U.S. Image-Guided Oncology Devices Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 11: U.S. Image-Guided Oncology Devices Market: Base Year Market Positioning, 2025
TABLE 12: U.S. Image-Guided Oncology Devices Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 13: U.S. Image-Guided Oncology Devices Market: Year-wise Market Size, 2021–2035 (US$ Billion)
TABLE 14: U.S. Image-Guided Oncology Devices Market: Cancer Treatment Infrastructure Snapshot
TABLE 15: U.S. Image-Guided Oncology Devices Market: High-Growth Opportunity Areas
TABLE 16: U.S. Image-Guided Oncology Devices Market: Drivers; Impact Analysis
TABLE 17: U.S. Image-Guided Oncology Devices Market: Restraints; Impact Analysis
TABLE 18: U.S. Image-Guided Oncology Devices Market: Opportunities; Impact Analysis
TABLE 19: U.S. Image-Guided Oncology Devices Market: Challenges; Impact Analysis
TABLE 20: U.S. Image-Guided Oncology Devices Market: Patent & Innovation Analysis, 2021–2025
TABLE 21: U.S. Image-Guided Oncology Devices Market: Clinical Workflow Economics Matrix
TABLE 22: U.S. Image-Guided Oncology Devices Market: Hospital Capital Procurement Behavior Matrix
TABLE 23: U.S. Image-Guided Oncology Devices Market: Radiation Oncology Equipment Replacement Cycle Analysis
TABLE 24: U.S. Image-Guided Oncology Devices Market: Interventional Oncology Procedure Economics
TABLE 25: U.S. Image-Guided Oncology Devices Market: Technology Adoption and Workflow Impact Matrix
TABLE 26: U.S. Image-Guided Oncology Devices Market: PESTEL Analysis
TABLE 27: U.S. Image-Guided Oncology Devices Market: Porter’s Five Forces Analysis
TABLE 28: U.S. Image-Guided Oncology Devices Market: Pricing Trend Analysis by Region, 2025–2035
TABLE 29: U.S. Image-Guided Oncology Devices Market: Value Chain Analysis
TABLE 30: U.S. Image-Guided Oncology Devices Market: Supply Chain Analysis
TABLE 31: U.S. Image-Guided Oncology Devices Market: Capital Equipment vs. Recurring Consumables Revenue Analysis
TABLE 32: U.S. Image-Guided Oncology Devices Market: Digitalization Impact Analysis
TABLE 33: U.S. Image-Guided Oncology Devices Market: AI and Automation Landscape
TABLE 34: U.S. Image-Guided Oncology Devices Market: Application & Innovation Landscape
TABLE 35: U.S. Image-Guided Oncology Devices Market: FDA Regulatory Framework Analysis
TABLE 36: U.S. Image-Guided Oncology Devices Market: CMS Reimbursement and Coverage Landscape
TABLE 37: U.S. Image-Guided Oncology Devices Market: Radiation Oncology Reimbursement Landscape
TABLE 38: U.S. Image-Guided Oncology Devices Market: Interventional Oncology Reimbursement Landscape
TABLE 39: U.S. Image-Guided Oncology Devices Market: Import/Export Restrictions & Tariff Impact
TABLE 40: U.S. Image-Guided Oncology Devices Market: Government Cancer Programs and Initiatives
TABLE 41: U.S. Image-Guided Oncology Devices Market: Impact of Escalating Geopolitical Tensions
TABLE 42: U.S. Image-Guided Oncology Devices Market: Hospital Value Analysis Committee Decision Framework
TABLE 43: U.S. Image-Guided Oncology Devices Market: Installed Base, Replacement and Upgrade Cycle Analysis
TABLE 44: U.S. Image-Guided Oncology Devices Market: Product Category Snapshot, 2025
TABLE 45: Segment Dashboard; Definition and Scope, by Product Category
TABLE 46: U.S. Image-Guided Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 47: U.S. Image-Guided Oncology Devices Market: Segment Share Analysis, by Product Category, 2025 & 2035 (%)
TABLE 48: Image-Guided Radiation Therapy Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 49: Image-Guided Tumor Ablation Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 50: Oncology Navigation and Robotic Guidance Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 51: Image-Guided Embolization and Targeted Therapy Delivery Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 52: Image-Guided Biopsy, Localization and Procedure Planning Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 53: Product Category Growth and Opportunity Ranking, 2025–2035
TABLE 54: U.S. Image-Guided Oncology Devices Market: Imaging Modality Snapshot, 2025
TABLE 55: Segment Dashboard; Definition and Scope, by Imaging Modality
TABLE 56: U.S. Image-Guided Oncology Devices Market, by Imaging Modality, 2021–2035 (US$ Billion)
TABLE 57: U.S. Image-Guided Oncology Devices Market: Segment Share Analysis, by Imaging Modality, 2025 & 2035 (%)
TABLE 58: CT and Cone-Beam CT Guidance Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 59: MRI Guidance Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 60: Ultrasound Guidance Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 61: Fluoroscopy and Angiography Guidance Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 62: PET, Optical and Other Hybrid Guidance Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 63: Imaging Modality Adoption and Growth Opportunity Matrix, 2025–2035
TABLE 64: U.S. Image-Guided Oncology Devices Market: Application Snapshot, 2025
TABLE 65: Segment Dashboard; Definition and Scope, by Application
TABLE 66: U.S. Image-Guided Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 67: U.S. Image-Guided Oncology Devices Market: Segment Share Analysis, by Application, 2025 & 2035 (%)
TABLE 68: Prostate Cancer Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 69: Lung Cancer Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 70: Liver Cancer and Hepatic Metastases Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 71: Breast Cancer Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 72: Brain and Central Nervous System Tumors Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 73: Kidney Cancer Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 74: Other Solid Tumors Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 75: Application Growth and Image-Guided Procedure Opportunity Matrix
TABLE 76: U.S. Image-Guided Oncology Devices Market: End User Snapshot, 2025
TABLE 77: Segment Dashboard; Definition and Scope, by End User
TABLE 78: U.S. Image-Guided Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 79: U.S. Image-Guided Oncology Devices Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 80: Hospitals and Integrated Health Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 81: Comprehensive Cancer Centers and Specialty Oncology Networks Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 82: Radiation Oncology Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 83: Academic and Research Medical Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 84: Ambulatory and Specialty Procedure Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 85: U.S. Image-Guided Oncology Devices Market: Regional Snapshot, 2025
TABLE 86: Segment Dashboard; Definition and Scope, by Geography
TABLE 87: U.S. Image-Guided Oncology Devices Market, by Region, 2021–2035 (US$ Billion)
TABLE 88: U.S. Image-Guided Oncology Devices Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 89: West Region U.S. Image-Guided Oncology Devices Market: Regional Overview and Trends
TABLE 90: West Region U.S. Image-Guided Oncology Devices Market: Key Manufacturers, Cancer Centers and Procurement Ecosystem
TABLE 91: West Region U.S. Image-Guided Oncology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 92: West Region U.S. Image-Guided Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 93: West Region U.S. Image-Guided Oncology Devices Market, by Imaging Modality, 2021–2035 (US$ Billion)
TABLE 94: West Region U.S. Image-Guided Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 95: West Region U.S. Image-Guided Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 96: California Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 97: Washington Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 98: Arizona Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 99: Colorado Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 100: Oregon Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 101: Utah Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 102: Nevada Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 103: New Mexico Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 104: Idaho Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 105: Montana Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 106: Wyoming Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 107: Alaska Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 108: Hawaii Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 109: Northeast Region U.S. Image-Guided Oncology Devices Market: Regional Overview and Trends
TABLE 110: Northeast Region U.S. Image-Guided Oncology Devices Market: Key Manufacturers, Cancer Centers and Procurement Ecosystem
TABLE 111: Northeast Region U.S. Image-Guided Oncology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 112: Northeast Region U.S. Image-Guided Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 113: Northeast Region U.S. Image-Guided Oncology Devices Market, by Imaging Modality, 2021–2035 (US$ Billion)
TABLE 114: Northeast Region U.S. Image-Guided Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 115: Northeast Region U.S. Image-Guided Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 116: New York Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 117: Massachusetts Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 118: New Jersey Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 119: Pennsylvania Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 120: Connecticut Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 121: Maine Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 122: Vermont Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 123: New Hampshire Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 124: Rhode Island Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 125: Delaware Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 126: South Region U.S. Image-Guided Oncology Devices Market: Regional Overview and Trends
TABLE 127: South Region U.S. Image-Guided Oncology Devices Market: Key Manufacturers, Cancer Centers and Procurement Ecosystem
TABLE 128: South Region U.S. Image-Guided Oncology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 129: South Region U.S. Image-Guided Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 130: South Region U.S. Image-Guided Oncology Devices Market, by Imaging Modality, 2021–2035 (US$ Billion)
TABLE 131: South Region U.S. Image-Guided Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 132: South Region U.S. Image-Guided Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 133: Texas Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 134: Florida Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 135: Georgia Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 136: North Carolina Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 137: Tennessee Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 138: South Carolina Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 139: Alabama Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 140: Mississippi Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 141: Louisiana Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 142: Arkansas Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 143: Kentucky Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 144: Oklahoma Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 145: Virginia Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 146: Maryland Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 147: West Virginia Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 148: Midwest Region U.S. Image-Guided Oncology Devices Market: Regional Overview and Trends
TABLE 149: Midwest Region U.S. Image-Guided Oncology Devices Market: Key Manufacturers, Cancer Centers and Procurement Ecosystem
TABLE 150: Midwest Region U.S. Image-Guided Oncology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 151: Midwest Region U.S. Image-Guided Oncology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 152: Midwest Region U.S. Image-Guided Oncology Devices Market, by Imaging Modality, 2021–2035 (US$ Billion)
TABLE 153: Midwest Region U.S. Image-Guided Oncology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 154: Midwest Region U.S. Image-Guided Oncology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 155: Illinois Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 156: Ohio Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 157: Michigan Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 158: Minnesota Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 159: Indiana Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 160: Wisconsin Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 161: Missouri Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 162: Iowa Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 163: Kansas Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 164: Nebraska Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 165: North Dakota Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 166: South Dakota Image-Guided Oncology Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 167: U.S. Image-Guided Oncology Devices Market: Competitive Landscape Snapshot, 2025
TABLE 168: U.S. Image-Guided Oncology Devices Market: Key Company Market Share Analysis, 2025
TABLE 169: U.S. Image-Guided Oncology Devices Market: Company Positioning Matrix
TABLE 170: U.S. Image-Guided Oncology Devices Market: Product Portfolio Benchmarking of Key Players
TABLE 171: U.S. Image-Guided Oncology Devices Market: Strategic Developments, FDA Clearances, Partnerships, M&A and Product Launches
TABLE 172: Siemens Healthineers / Varian: Company Profile
TABLE 173: Elekta: Company Profile
TABLE 174: Accuray Incorporated: Company Profile
TABLE 175: GE HealthCare: Company Profile
TABLE 176: Philips: Company Profile
TABLE 177: Canon Medical Systems USA: Company Profile
TABLE 178: United Imaging Healthcare: Company Profile
TABLE 179: IBA: Company Profile
TABLE 180: Mevion Medical Systems: Company Profile
TABLE 181: Brainlab: Company Profile
TABLE 182: C-RAD: Company Profile
TABLE 183: Vision RT: Company Profile
TABLE 184: Medtronic: Company Profile
TABLE 185: Boston Scientific Corporation: Company Profile
TABLE 186: Johnson & Johnson MedTech / Ethicon: Company Profile
TABLE 187: AngioDynamics: Company Profile
TABLE 188: Merit Medical Systems: Company Profile
TABLE 189: Terumo Interventional Systems: Company Profile
TABLE 190: Cook Medical: Company Profile
TABLE 191: HistoSonics: Company Profile
TABLE 192: Profound Medical: Company Profile
TABLE 193: INSIGHTEC: Company Profile
TABLE 194: Monteris Medical: Company Profile
TABLE 195: IceCure Medical: Company Profile
TABLE 196: Quantum Surgical: Company Profile
TABLE 197: U.S. Image-Guided Oncology Devices Market: Future Market Scenario Analysis, 2026–2035
TABLE 198: U.S. Image-Guided Oncology Devices Market: Disruptive Technologies Impact Matrix
TABLE 199: U.S. Image-Guided Oncology Devices Market: Emerging Business Trends
TABLE 200: U.S. Image-Guided Oncology Devices Market: Business Opportunities for Startups and Existing Players
TABLE 201: U.S. Image-Guided Oncology Devices Market: Investment Prioritization Matrix
TABLE 202: U.S. Image-Guided Oncology Devices Market: Technology Adoption Curve, 2026–2035
TABLE 203: U.S. Image-Guided Oncology Devices Market: Capital Replacement Opportunity Analysis
TABLE 204: U.S. Image-Guided Oncology Devices Market: High-Growth Product–Application Opportunity Matrix
TABLE 205: U.S. Image-Guided Oncology Devices Market: Regional Opportunity Prioritization Matrix
TABLE 206: U.S. Image-Guided Oncology Devices Market: Strategic Recommendations for Device Manufacturers
TABLE 207: U.S. Image-Guided Oncology Devices Market: Strategic Recommendations for Radiation Oncology Technology Companies
TABLE 208: U.S. Image-Guided Oncology Devices Market: Strategic Recommendations for Interventional Oncology Device Manufacturers
TABLE 209: U.S. Image-Guided Oncology Devices Market: Strategic Recommendations for Hospitals and Health Systems
TABLE 210: U.S. Image-Guided Oncology Devices Market: Strategic Recommendations for Comprehensive Cancer Centers
TABLE 211: U.S. Image-Guided Oncology Devices Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 212: U.S. Image-Guided Oncology Devices Market: Strategic Recommendations for Distributors and Channel Partners
TABLE 213: U.S. Image-Guided Oncology Devices Market: Strategic Recommendations for New Entrants and Startups
TABLE 214: U.S. Image-Guided Oncology Devices Market: Go-to-Market Strategy Considerations
TABLE 215: U.S. Image-Guided Oncology Devices Market: Product Positioning and Portfolio Expansion Guidance
TABLE 216: U.S. Image-Guided Oncology Devices Market: FDA and Reimbursement Commercialization Considerations
TABLE 217: U.S. Image-Guided Oncology Devices Market: State-Level Market Entry Prioritization
TABLE 218: U.S. Image-Guided Oncology Devices Market: Strategic Partnership and Clinical Evidence Roadmap
TABLE 219: U.S. Image-Guided Oncology Devices Market: Scope Limitation
TABLE 220: U.S. Image-Guided Oncology Devices Market: Market Definition Limitation
TABLE 221: U.S. Image-Guided Oncology Devices Market: Data Use Limitation
TABLE 222: U.S. Image-Guided Oncology Devices Market: Forecasting Limitation
TABLE 223: U.S. Image-Guided Oncology Devices Market: Clinical and Regulatory Information Limitation
TABLE 224: U.S. Image-Guided Oncology Devices Market: Legal and Third-Party Data Disclaimer

List of Figures

FIGURE 1: U.S. Image-Guided Oncology Devices Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: U.S. Image-Guided Oncology Devices Market Ecosystem
FIGURE 4: Stakeholder Ecosystem and Commercial Interaction Framework
FIGURE 5: U.S. Image-Guided Oncology Devices Market Executive Snapshot, 2025
FIGURE 6: Market Attractiveness Analysis
FIGURE 7: U.S. Image-Guided Oncology Devices Market Size, Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 8: U.S. Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 9: U.S. Image-Guided Oncology Devices Market Year-wise Growth Curve, 2021–2035
FIGURE 10: U.S. Cancer Treatment Infrastructure and Image-Guided Oncology Opportunity Map
FIGURE 11: High-Growth Opportunity Areas, 2026–2035
FIGURE 12: U.S. Image-Guided Oncology Devices Market Dynamics
FIGURE 13: Drivers Impact Analysis
FIGURE 14: Restraints and Challenges Impact Analysis
FIGURE 15: Innovation & Patent Landscape, 2021–2025
FIGURE 16: Image-Guided Oncology Clinical Workflow Economics Framework
FIGURE 17: Hospital Capital Procurement Decision Framework
FIGURE 18: Radiation Oncology Equipment Replacement Cycle
FIGURE 19: Interventional Oncology Procedure Economics Framework
FIGURE 20: PESTEL Analysis
FIGURE 21: Porter’s Five Forces Analysis
FIGURE 22: Value Chain Analysis
FIGURE 23: Supply Chain Analysis
FIGURE 24: AI, Automation and Digital Oncology Technology Landscape
FIGURE 25: FDA, CMS and Reimbursement Environment Framework
FIGURE 26: Product Category Segment Market Share Analysis, 2025 & 2035
FIGURE 27: Product Category Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 28: Image-Guided Radiation Therapy Systems Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 29: Image-Guided Tumor Ablation Systems Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 30: Oncology Navigation and Robotic Guidance Systems Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 31: Image-Guided Embolization and Targeted Therapy Delivery Devices Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 32: Image-Guided Biopsy, Localization and Procedure Planning Devices Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 33: Imaging Modality Segment Market Share Analysis, 2025 & 2035
FIGURE 34: Imaging Modality Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 35: CT and Cone-Beam CT Guidance Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 36: MRI Guidance Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 37: Ultrasound Guidance Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 38: Fluoroscopy and Angiography Guidance Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 39: PET, Optical and Other Hybrid Guidance Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 40: Application Segment Market Share Analysis, 2025 & 2035
FIGURE 41: Application Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 42: Prostate Cancer Image-Guided Oncology Devices Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 43: Lung Cancer Image-Guided Oncology Devices Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 44: Liver Cancer and Hepatic Metastases Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 45: Breast Cancer Image-Guided Oncology Devices Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 46: Brain and Central Nervous System Tumors Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 47: Kidney Cancer Image-Guided Oncology Devices Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 48: Other Solid Tumors Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 49: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 50: End User Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 51: Hospitals and Integrated Health Systems Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 52: Comprehensive Cancer Centers and Specialty Oncology Networks Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 53: Radiation Oncology Centers Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 54: Academic and Research Medical Centers Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 55: Ambulatory and Specialty Procedure Centers Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 56: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 57: Regional Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 58: West Region U.S. Image-Guided Oncology Devices Market Share and Leading Players, 2025
FIGURE 59: West Region Market Share Analysis by State, 2025
FIGURE 60: West Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 61: California Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 62: Washington Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 63: Arizona Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 64: Colorado Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 65: Oregon Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 66: Utah Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 67: Nevada Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 68: New Mexico Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 69: Idaho Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 70: Montana Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 71: Wyoming Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 72: Alaska Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 73: Hawaii Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 74: Northeast Region U.S. Image-Guided Oncology Devices Market Share and Leading Players, 2025
FIGURE 75: Northeast Region Market Share Analysis by State, 2025
FIGURE 76: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 77: New York Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 78: Massachusetts Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 79: New Jersey Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 80: Pennsylvania Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 81: Connecticut Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 82: Maine Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 83: Vermont Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 84: New Hampshire Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 85: Rhode Island Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 86: Delaware Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 87: South Region U.S. Image-Guided Oncology Devices Market Share and Leading Players, 2025
FIGURE 88: South Region Market Share Analysis by State, 2025
FIGURE 89: South Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 90: Texas Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 91: Florida Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 92: Georgia Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 93: North Carolina Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 94: Tennessee Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 95: South Carolina Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 96: Alabama Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 97: Mississippi Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 98: Louisiana Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 99: Arkansas Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 100: Kentucky Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 101: Oklahoma Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 102: Virginia Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 103: Maryland Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 104: West Virginia Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 105: Midwest Region U.S. Image-Guided Oncology Devices Market Share and Leading Players, 2025
FIGURE 106: Midwest Region Market Share Analysis by State, 2025
FIGURE 107: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 108: Illinois Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 109: Ohio Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 110: Michigan Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 111: Minnesota Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 112: Indiana Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 113: Wisconsin Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 114: Missouri Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 115: Iowa Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 116: Kansas Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 117: Nebraska Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 118: North Dakota Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 119: South Dakota Image-Guided Oncology Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 120: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 121: Company Positioning Matrix
FIGURE 122: Key Player Product Portfolio Benchmarking
FIGURE 123: Strategic Developments, FDA Clearances, Partnerships, M&A and Product Launches
FIGURE 124: U.S. Image-Guided Oncology Device Innovation Roadmap
FIGURE 125: Adaptive Radiation Therapy Adoption Roadmap, 2026–2035
FIGURE 126: MRI-Guided Oncology Technology Opportunity Map
FIGURE 127: Robotic and Navigated Tumor Intervention Growth Roadmap
FIGURE 128: Histotripsy and Non-Thermal Tumor Ablation Adoption Roadmap
FIGURE 129: AI-Assisted Image Guidance and Treatment Planning Opportunity Map
FIGURE 130: Future Market Scenario Analysis, 2026–2035
FIGURE 131: Disruptive Technologies Impact Matrix
FIGURE 132: Emerging Business Trends Matrix
FIGURE 133: Technology Adoption Curve, 2026–2035
FIGURE 134: Capital Replacement Opportunity Matrix
FIGURE 135: Investment Prioritization Matrix
FIGURE 136: Product–Application Growth Opportunity Matrix
FIGURE 137: Regional Market Opportunity Prioritization
FIGURE 138: Strategic Growth Roadmap for U.S. Image-Guided Oncology Device Companies
FIGURE 139: Go-to-Market Strategy Framework
FIGURE 140: Product Positioning and Portfolio Expansion Framework
FIGURE 141: State-Level Market Entry Prioritization Framework
FIGURE 142: Strategic Partnership and Clinical Evidence Roadmap
FIGURE 143: Report Scope, Limitations and Disclaimer Framework